Efficacy and safety of cefovecin in treating bacterial folliculitis, abscesses, or infected wounds in dogs

Journal of the American Veterinary Medical Association

Volumn 233, Issue 3, 2008, Pages 433-439

  Six, Robert ^a   Cherni, Judy ^a   Chesebrough, Robert ^a   Cleaver, Dawn ^a   Lindeman, Cindy J ^a   Papp, Georg ^a   Skogerboe, Terry L ^a   Weigel, Daniel J ^a   Boucher, Joseph F ^a   Stegemann, Michael R ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFADROXIL; CEFOVECIN; CEPHALOSPORIN DERIVATIVE;

ABSCESS; ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; FEMALE; FOLLICULITIS; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SAFETY; TREATMENT OUTCOME; WOUND INFECTION;

ABSCESS; ANIMALS; ANTI-BACTERIAL AGENTS; CEFADROXIL; CEPHALOSPORINS; DOG DISEASES; DOGS; FEMALE; FOLLICULITIS; MALE; SAFETY; TREATMENT OUTCOME; WOUND INFECTION;

ANIMALIA; BACTERIA (MICROORGANISMS); CANIS FAMILIARIS;

EID: 48749129834     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.233.3.433     Document Type: Article

References (28)

1. Scott D, Miller WH. Bacterial skin diseases. In: Muller W, ed. Muller and Kirk's small animal dermatology. 6th ed. Philadelphia: WB Saunders Co, 2001;274-335.
2. Boothe D. Treatment of bacterial infections. In: Small animal clinical pharmacology and therapeutics. Philadelphia: WB Saunders Co, 2001;191.
3. Harvey RG, Lloyd DH. The distribution of Staphylococcus intermedius and coagulase-negative staphylococci on the hair, skin surface, within the hair follicles and on the mucous membranes of dogs. Vet Dermatol 1994;5:75-81.
4. McEwan NA. Adherence by Staphylococcus intermedius to canine keratinocytes in atopic dermatitis. Res Vet Sci 2000;68:279-283.
5. Mason IS, Kietzmann M. Cephalosporins - pharmacological basis of clinical use in veterinary dermatology. Vet Dermatol 1999;10:187-192.
6. CEFA-TABS (cefadroxil). Freedom of information summary. NADA 119-688. Approved July 20, 1988. Available at: www. fda.gov/cvm/FOI/1467.htm. Accessed Apr 9, 2008.
7. Tablets S. (cefpodoxime proxetil). Freedom of information summary. NADA 141-232. Approved July 22, 2004. Available at: www. fda.gov/cvm/FOI/141- 232072204.pdf. Accessed Apr 8, 2008.
8. Frank LA, Kunkle GA. Comparison of the efficacy of cefadroxil and generic and proprietary cephalexin in the treatment of pyoderma in dogs. J Am Vet Med Assoc 1993;203:530-533.
9. DeBoer D. Management of the chronic and recurrent pyoderma in the dog. In: Bonagura J, ed. Kirk's current veterinary therapy XII. Philadelphia: WB Saunders Co, 1995;611-617.
10. Stegemann MR, Passmore CA, Sherington J, et al. Antimicrobial activity and spectrum of cefovecin, a new extended-spectrum cephalosporin, against pathogens collected from dogs and cats in Europe and North America. Antimicrob Agents Chemother 2006;50:2286-2292.
11. Stegemann MR, Sherington J, Blanchflower S. Pharmacokinetics and pharmacodynamics of cefovecin in dogs. J Vet Pharmacol Ther 2006;29:501-511.
12. Stegemann MR, Coati N, Passmore CA, et al. Clinical efficacy and safety of cefovecin in the treatment of canine pyoderma and wound infections. J Small Anim Pract 2007;48:378-386.
13. Convenia (cefovecin). Freedom of information summary. NADA 141-285. New York: Pfizer Inc, 2008.
14. FDA-CVM. Guidance for industry #85. Good clinical practice. VICH GL9. May 9, 2001. Available at: www.fda.gov/cvm/Guidance/guide85.PDF. Accessed Apr 9, 2008.
15. Murray PR, Baron EJ, Pfaller MA, et al. Manual of clinical microbiology. 7th ed. Washington, DC: American Society of Microbiology, 1999.
16. Quinn PJ, Markey BK, Carter ME, et al. Veterinary microbiology and microbial disease. Oxford, England: Blackwell Science Ltd, 2002.
17. NCCLS. Performance standards for antimicrobial disc and dilution susceptibility tests for bacteria isolated from animals; approved standard. M31, 2nd ed. Wayne, Pa: NCCLS, 2002.
18. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of 11 methods. Stat Med 1998;17:873-890.
19. Normand EH, Gibson NR, Taylor DJ, et al. Trends of antimicrobial resistance in bacterial isolates from a small animal referral hospital. Vet Rec 2000;146:151-155.
20. Ganiere JP, Medaille C, Mangion C. Antimicrobial drug susceptibility of Staphylococcus intermedius clinical isolates from canine pyoderma. J Vet Med B Infect Dis Vet Public Health 2005;52:25-31.
21. Angarano DW, MacDonald JM. Efficacy of cefadroxil in the treatment of bacterial dermatitis in dogs. J Am Vet Med Assoc 1989;194:57-59.
22. Paradis M, Lemay S, Scott D, et al. Efficacy of enrofloxacin in the treatment of canine bacterial pyoderma. Vet Dermatol 1990;1:123-127.
23. Scott DW, Miller WH, Wellington JR. The combination of ormetoprim and sulfadimethoxine in the treatment of pyoderma due to Staphylococcus intermedium infection in dogs. Canine Pract 1993;18(2):29-33.
24. Lloyd DH, Carlotti DN, Koch HJ, et al. Treatment of canine pyoderma with co-amoxyclav: a comparison of two dose rates. Vet Rec 1997;141:439-441.
25. Guardabassi L, Schwarz S, Lloyd DH. Pet animals as reservoirs of antimicrobial-resistant bacteria. J Antimicrob Chemother 2004;54:321-332.
26. American Animal Hospital Association. Basic guidelines of judicious therapeutic use of antimicrobials (Approved by the AVMA Executive Board November 2006). Available at: www.avma.org/issues/policy/jtua_aafp_aaha.asp. Accessed Apr 9, 2008.
27. Grave K, Tanem H. Compliance with short-term oral antibacterial drug treatment in dogs. J Small Anim Pract 1999;40:158-162.
28. Adams VJ, Campbell JR, Waldner CL, et al. Evaluation of client compliance with short-term administration of antimicrobials to dogs. J Am Vet Med Assoc 2005;226:567-574.